We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

70 hedge funds and large institutions have $34M invested in Theriva Biologics in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

17% more funds holding

Funds holding: 60 → 70 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

44% less capital invested

Capital invested by funds: $60.8M → $34M (-$26.8M)

Holders
70
Holders Change
+10
Holders Change %
+16.67%
% of All Funds
1.75%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
20
Increased
21
Reduced
9
Closed
9
Calls
$7.97M
Puts
–
Net Calls
+$7.97M
Net Calls Change
+$7.97M

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$5.38M
2
SM
Sabby Management
Florida
+$3.56M
3
MP
MSD Partners
New York
+$1.18M
4
UOC
UBS O'Connor
Illinois
+$1.17M
5
Millennium Management
Millennium Management
New York
+$883K

Top Sellers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
-$1.99M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.14M
3
William Blair & Company
William Blair & Company
Illinois
-$411K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$131K
5
RCP
Rothschild Capital Partners
New York
-$52K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$10.1M – – –
Alyeska Investment Group
2
Alyeska Investment Group
Illinois
$3.5M +$5.38M +524 New
MP
3
MSD Partners
New York
$3.14M +$1.18M +115 +32%
SM
4
Sabby Management
Florida
$2.31M +$3.56M +347 New
BFA
5
BlackRock Fund Advisors
California
$1.87M +$462K +45 +19%
KCM
6
Knoll Capital Management
Florida
$1.55M -$1.99M -194 -45%
BIT
7
BlackRock Institutional Trust
California
$1.4M +$51.3K +5 +2%
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.38M -$1.14M -111 -35%
William Blair & Company
9
William Blair & Company
Illinois
$1.26M -$411K -40 -18%
UOC
10
UBS O'Connor
Illinois
$763K +$1.17M +114 New
State Street
11
State Street
Massachusetts
$727K +$10.3K +1 +0.9%
Northern Trust
12
Northern Trust
Illinois
$722K +$133K +13 +14%
Millennium Management
13
Millennium Management
New York
$576K +$883K +86 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$409K +$41.1K +4 +7%
Norges Bank
15
Norges Bank
Norway
$356K – – –
BCM
16
Bridgeway Capital Management
Texas
$336K -$10.3K -1 -2%
Morgan Stanley
17
Morgan Stanley
New York
$300K +$318K +31 +221%
EDRH
18
Edmond de Rothschild Holding
Switzerland
$282K +$92.4K +9 +27%
BIM
19
BlackRock Investment Management
Delaware
$223K +$10.3K +1 +3%
TCIM
20
TIAA CREF Investment Management
New York
$200K +$10.3K +1 +3%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$196K – – –
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$154K +$51.3K +5 +28%
UBS Group
23
UBS Group
Switzerland
$148K +$61.6K +6 +38%
VKH
24
Virtu KCG Holdings
New York
$133K +$175K +17 +567%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$133K +$205K +20 New
1
2 3 4

TOVX Hedge Fund Activity: Q4 2016 in Review

70 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2016, worth a combined $34M — down 44% from $60.8M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TOVX positions and 9 closed out — a net gain of 11 holders — while 21 added to existing stakes and 9 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $5.38M. The largest seller was Knoll Capital Management, cutting an estimated $1.99M.

  • 70 institutional investors held Theriva Biologics (TOVX) as of Q4 2016, up from 60 in Q3 2016.
  • Funds reported $34M of Theriva Biologics stock for Q4 2016, down 44% quarter-over-quarter.
  • 20 funds opened new Theriva Biologics positions in Q4 2016 and 9 closed out, a net change of +11 holders.
  • The largest Theriva Biologics buyer in Q4 2016 was Alyeska Investment Group, an estimated $5.38M added.
  • The largest Theriva Biologics seller in Q4 2016 was Knoll Capital Management, an estimated $1.99M sold.

Based on aggregated 13F filings for Q4 2016.